References
- Steenbergen JN, Alder J, Thorne GM, Tally FP. Daptomycin: A lipopeptide antibiotic for the treatment of seri-ous Gram-positive infections. J Antimicrob Chemother 2005; 55: 574–578
- Silverman JA, Perlmutter NC, Shapiro HM. Correlation of daptomycin bactericidal activity and membrane depolariza-tion in Staphylococcus aureus. Antimicrob Agents Chemother 2003; 47: 2538–2544.
- Package Insert. Cubicin (daptomycin for injection). Lexington MA [Cubist Pharmaceuticals, Inc.]. Available at http://www.cubist.com/shared/cubicinlabel.pdf. Accessed on September 22, 2003.
- Carpenter CF, Chambers HF. Daptomycin: Another novel agent for treating infections due to drug-resistant Gram-positive pathogens. Clin Infect Dis 2004; 38: 994–1000.
- Laganas V, Alder J, Silverman JA. In vitro bactericidal activities of daptomycin against Staphylococcus aureus and Enterococcus faecalis are not mediated by inhibition of lipote-ichoic acid biosynthesis. Antimicrob Agents Chemother 2003; 47: 2682–2684.
- Dandekar PK, Tessier PR, Williams P, Nightingale CH, Nicolau DP. Pharmacodynamic profile of daptomycin against Enterococcus species and methicillin-resistant Staphylococcus aureus in a murine thigh infection model. J Antimicrob Chemother 2003; 52: 405–411.
- Dvorchik BH, Brazier D, DeBruin MF, Arbeit RD. Daptomycin pharmacokinetics and safety following administra-tion of escalating doses once daily to healthy subjects. Antimicrob Agents Chemother 2003; 47: 1318–1323.
- Arbeit RD, Make D, Tally FP, Campanaro E, Eisenstein BI, The Daptomycin 98-01 and 99-01 Investigators. The safe-ty and efficacy of daptomycin for the treatment of complicated skin and skin-structure infections. Clin Infect Dis 2004; 38: 1673–1681.
- Sakouloas G, Eliopoulos GM, Alder J, Thauvin-Eliopoulos C. Efficacy of daptomycin in experimental endo-carditis due to methicillin-resistant Staphylococcus aureus. Antimicrob Agents Chemother 2003; 47: 1714–1718.
- Streit JM, Jones RN, Sader HS. Daptomycin activity and spectrum: a worldwide sample of 6,737 Gram-positive organisms. J Antimicrob Chemother 2004; 53: 669–674.
- Sader HS, Streit JM, Fritsche TR, Jones RN. Antimicrobial activity of daptomycin against multi-drug-resis-tant gram-positive strains collected worldwide. Diagn Microbiol Infect Dis 2004; 50:201:204.
- Critchley IA, Draghi DC, Sahm DF, Thornsberry C, Jones ME, Karlowksy JA. Activity of daptomycin against sus-ceptible and multidrug-resistant Gram-positive pathogens col-lected in the SECURE study (Europe) during 2000-2001. J Antimicrob Chemother 2003; 51: 639–649.
- Fluit AD, Schmitz F-J, Verhoef J, Milatovic D. Daptomycin in vitro susceptibility in European Gram-positive clinical isolates. Intern J Antimicrob Agents 2004; 24: 59–66.
- Johnson AP, Mushtaq S, Warner M, Livermore DM. Activity of daptomycin against multi-resistant Gram-positive bacteria including enterococci and Staphylococcus aureus resistant to linezolid. Intern J Antimicrob Agents 2004; 24: 315–319.
- Wise R, Andrews JM, Ashby JP. Activity of daptomycin against Gram-positive pathogens: A comparison with other agents and the determination of a tentative breakpoint. J Antimicrob Chemother 2001; 48: 563–567.
- National Committee for Clinical Laboratory Standards. Methods for dilution antimicrobial susceptibility tests for bacte-ria that grow aerobically. Approved standard M7-A6. Wayne, PA: NCCLS, 2003.
- Fuchs PC, Barry AL, Brown SD. Daptomycin suscepti-bility tests: Interpretive criteria, quality control and effect of calcium on in vitro tests. Diagn Microbiol Infect Dis 2000; 38: 51–58.
- Clinical and Laboratory Standards Institute. Performance standards for antimicrobial susceptibility testing, 15th information supplement M100-515. Wayne, PA: CLSI, 2005.
- Biedenbach DJ, Moet GJ, Jones RN. Occurrence and antimicrobial resistance pattern comparisons among blood-stream infection isolates from the SENTRY Antimicrobial Surveillance Program (1997-2002). Diagn Microbiol Infect Dis 2004; 50: 59–69.
- Streit JM, Jones RN, Sader HS, Fritsche TR. Assessment of pathogen occurrences and resistance profiles among infected patients in the intensive care unit: Report from the SENTRY Antimicrobial Surveillance Program (North America, 2001). Intern J Antimicrob Agents 2004; 24: 111–118.
- EARSS Annual Report. 2003. http://www.earss.rivm.nl. Accessed June 10, 2005.
- Deshpande LM, Fritsche TR, Jones RN. Molecular epi-demiology of selected multidrug-resistant bacteria. A global report from the SENTRY Antimicrobial Surveillance Program. Diagn Microbiol Infect Dis 2004; 49: 231–236.